Chris Karlovich

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman et al. · New England Journal of Medicine · 2015 · 664 citations · Full text

Medicine, Oncology, Pharmacology +14

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy et al. · Nature Communications · 2016 · 659 citations · Full text

Medicine, Oncology, Pharmacology +17

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Yingdong Zhao, Ming‐Chung Li, Mariam M. Konaté et al. · Journal of Translational Medicine · 2021 · 521 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Zofia Piotrowska, Matthew J. Niederst, Chris Karlovich et al. · Cancer Discovery · 2015 · 460 citations · Full text

Medicine, Oncology, Pharmacology +16

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Karen L. Reckamp, Vladislava O. Melnikova, Chris Karlovich et al. · Journal of Thoracic Oncology · 2016 · 285 citations · Full text

Medicine, Oncology, Pharmacology +17